Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells

References

• Danilov AV, Danilova OV, Klein AK, et al. Molecular pathogenesis of chronic lymphocytic leukemia. Curr Mol Med 2006;6:665–675.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 1996;87:2615–2620.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563–574.
   PubMed Web of Science ®Google Scholar
• Davids MS, Deng J, Wiestner A, et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012;120:3501–3509.
   PubMed Web of Science ®Google Scholar
• Danilov AV. Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther 2013;35:1258–1270.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286–2294.
   PubMed Web of Science ®Google Scholar
• Hewamana S, Lin TT, Rowntree C, et al. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol 2009;27:763–769.
   PubMed Web of Science ®Google Scholar
• Liu Z, Hazan-Halevy I, Harris DM, et al. STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Mol Cancer Res 2011;9:507–515.
   PubMed Web of Science ®Google Scholar
• Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012–1020.
   PubMed Web of Science ®Google Scholar
• Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 2014;123:3286–3295.
   PubMed Web of Science ®Google Scholar
• Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 2011;244:115–133.
   PubMed Web of Science ®Google Scholar
• Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009;15:3912–3916.
   PubMed Web of Science ®Google Scholar
• Milhollen MA, Traore T, Adams-Duffy J, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010;116:1515–1523.
   PubMed Web of Science ®Google Scholar
• Mathewson N, Toubai T, Kapeles S, et al. Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood 2013;122:2062–2073.
   PubMed Web of Science ®Google Scholar
• Swords RT, Kelly KR, Smith PG, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010;115:3796–3800.
   PubMed Web of Science ®Google Scholar
• Gu Y, Kaufman JL, Bernal L, et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood 2014;123:3269–3276.
   PubMed Web of Science ®Google Scholar
• Godbersen JC, Humphries LA, Danilova OV, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res 2014;20:1576–1589.
   PubMed Web of Science ®Google Scholar
• Humphries LA, Godbersen JC, Danilova OV, et al. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia. Br J Haematol 2013;163:590–602.
   PubMed Web of Science ®Google Scholar
• Yoon JY, Lafarge S, Dawe D, et al. Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:1735–1742.
   PubMed Web of Science ®Google Scholar
• Talab F, Allen JC, Thompson V, et al. LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells. Mol Cancer Res 2013;11:541–554.
   PubMed Web of Science ®Google Scholar
• Tromp JM, Tonino SH, Elias JA, et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010;29:5071–5082.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Erba HP, Maris MB, et al. MLN4924, a novel investigational inhibitor of NEDD8-activating enzyme (NAE), in adult patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): results from multiple dosing schedules in a phase 1 study. Blood 2013;122(Suppl. 1): Abstract 1443.
   Google Scholar
• Saiya-Cork K, Collins R, Parkin B, et al. A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2679–2692.
   PubMed Web of Science ®Google Scholar
• Danilov AV, Soderquist RS, Bates DJ, et al. Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts. Expert Rev Anticancer Ther 2013;13:1009–1012.
   PubMed Web of Science ®Google Scholar